Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Nerve Block of the Vastus Medialis and Anterior Obturator Branch in Anterior Cruciate Ligament Reconstruction With DIDT Graft (RECUP-NVM)

The goal of this randomized clinical trial is to evaluate whether a targeted regional anesthesia strategy combining an adductor canal block, a nerve to the vastus medialis (NVM) block, an anterior obturator nerve branch block, and an iPACK block improves postoperative recovery in patients undergoing anterior cruciate ligament (ACL) reconstruction using a hamstring tendon (semitendinosus and gracilis; DIDT) graft, compared with the standard analgesic protocol used in participating centres, consisting of a femoral nerve block combined with an iPACK block.

The main question the study aims to answer is whether this targeted combination of nerve blocks, compared with the standard femoral nerve block plus iPACK regimen, improves the quality of postoperative recovery, as measured by the Quality of Recovery-15 (QoR-15) score at 24 hours after surgery.

The study hypothesis is that the targeted adductor canal + NVM + anterior obturator branch + iPACK strategy will significantly improve postoperative recovery quality at 24 hours compared with the standard femoral nerve block + iPACK protocol, with an expected improvement of at least 8 points on the QoR-15 score. This 8-point difference represents the minimal clinically important difference (MCID) for this questionnaire (Léger et al., 2020). The QoR-15 is a validated global recovery assessment tool, available in French, and sensitive to variations in recovery quality in outpatient orthopedic surgery (Nakase et al., 2021). An improvement of at least 8 points at 24 hours would therefore indicate a clinically meaningful benefit from the patient's perspective.

The study will also assess:

  • Postoperative pain at rest and during mobilization.
  • Opioid consumption during the first 48 hours after surgery.
  • Incidence of postoperative nausea and vomiting.
  • Time to first ambulation.
  • Postoperative thigh edema.
  • Neuromuscular recovery of the thigh.
  • Patient satisfaction with analgesic management.
  • Adverse events related to regional anesthesia.

Participants will be randomly assigned to one of two treatment groups. All participants will undergo ACL reconstruction with a DIDT graft. Participants in the comparator group will receive a femoral nerve block combined with an iPACK block. Participants in the intervention group will receive a targeted regional anesthesia strategy combining an adductor canal block, a nerve to the vastus medialis (NVM) block, an anterior branch of the obturator nerve block, and an iPACK block.

The planned volumes and doses for each block in the two randomized strategies are detailed as follows: Compared with the control group, which receives a femoral nerve block with 15 mL and an iPACK block with 20 mL of ropivacaine 0.35% (total volume: 35 mL; total dose: 122.5 mg), the intervention group receives an adductor canal block with 10 mL, a nerve to the vastus medialis block with 5 mL, an anterior branch of the obturator nerve block with 6 mL, and an iPACK block with 20 mL of ropivacaine 0.35% (total volume: 41 mL; total dose: 143.5 mg). Thus, the intervention group involves two additional nerve block targets and an additional 6 mL of ropivacaine, corresponding to an additional dose of 21 mg (+17.1%) compared with the control group. The cumulative dose will be checked against the patient-specific safety limits before performing the blocks. Patients in whom the blocks cannot be safely performed within these limits will not be included.

Postoperative assessments will include pain scores, QoR-15 questionnaires, opioid consumption, nausea and vomiting, thigh measurements, and neuromuscular function assessments during the first 48 hours after surgery. Patient satisfaction and safety outcomes will also be assessed during follow-up.

The primary outcome will compare the QoR-15 score at 24 hours between the two groups, with an 8-point difference considered clinically meaningful.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

108

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 60 anni (Adulto)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Adult patients aged 18 to 60 years.
  • Patients with a primary anterior cruciate ligament (ACL) injury.
  • Patients scheduled for ACL reconstruction using a DIDT graft under general anesthesia.
  • Patients managed as ambulatory surgery or short stay.
  • Patients who understand the validated French version of the QoR-15 questionnaire.
  • Patients who have given written informed consent to participate in the study.
  • Patients affiliated with or beneficiaries of a social security system.

Exclusion Criteria:

  • Patients with a body weight below 50 kg, as the planned cumulative ropivacaine dose could exceed the safety limit of 3 mg/kg.
  • Patients with allergy to local anesthetics or a contraindication to peripheral nerve blocks.
  • Patients with lower-limb neuropathy.
  • Patients with coagulation disorders or on major anticoagulation.
  • Patients with chronic pain requiring more than 30 mg morphine-equivalents per day.
  • Patients undergoing revision ACL reconstruction or a major combined surgical procedure.
  • Pregnant women.
  • Patients unable to complete the questionnaires or who refuse to participate.
  • Pregnant women or women who may be pregnant (of childbearing potential without effective contraception) or who are breastfeeding.
  • Protected adults: patients under guardianship, curatorship or other legal protection, deprived of liberty, or unable to provide informed consent.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Adductor Canal + iPACK + NVM and Anterior Obturator Nerve Blocks

Participants will undergo anterior cruciate ligament reconstruction using a semitendinosus and gracilis (DIDT) graft. They will receive a targeted regional anesthesia protocol consisting of an adductor canal block, a nerve to the vastus medialis (NVM) block, an iPACK block, and a block of the anterior branch of the obturator nerve.

Ultrasound-guided infiltration between the popliteal artery and the posterior capsule of the knee (iPACK) administered as part of the regional anesthesia protocol.

Ultrasound-guided nerve block targeting the nerve to the vastus medialis (NVM), administered in addition to theadductor canal and iPACK blocks in the experimental arm.

Ultrasound-guided block of the anterior branch of the obturator nerve, administered in addition to the adductor canal and iPACK blocks in the experimental arm.

Ultrasound-guided adductor canal block administered as part of the targeted regional anesthesia protocol for ACL reconstruction in the experimental arm.

Comparatore attivo: Femoral + iPACK Nerve Blocks

Participants will undergo anterior cruciate ligament reconstruction using a semitendinosus and gracilis (DIDT) graft. They will receive the standard regional anesthesia protocol consisting of a femoral nerve block and an iPACK block, without additional nerve blocks of the nerve to the vastus medialis (NVM) or anterior branch of the obturator nerve.

Ultrasound-guided infiltration between the popliteal artery and the posterior capsule of the knee (iPACK) administered as part of the regional anesthesia protocol.

Ultrasound-guided femoral nerve block administered as part of the standard regional anesthesia protocol for ACL reconstruction.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Quality of Recovery (QoR-15) Score
Lasso di tempo: Baseline (preoperatively, before regional anesthesia) and 24 hours after surgery

The quality of postoperative recovery will be assessed using the Quality of Recovery-15 (QoR-15) questionnaire. The QoR-15 score ranges from 0 to 150, with higher scores indicating better quality of recovery. The primary analysis will compare the change in QoR-15 score from baseline to 24 hours postoperatively between the experimental and active comparator groups. An 8-point difference between groups is considered the minimal clinically important difference.

Baseline (preoperatively, before regional anesthesia) and 24 hours after surgery

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Postoperative Pain
Lasso di tempo: 6, 24, and 48 hours after surgery

Pain intensity will be assessed using the Numeric Rating Scale (NRS), both at rest and during mobilization. The NRS ranges from 0 (no pain) to 10 (worst pain imaginable).

6, 24, and 48 hours after surgery
Postoperative Opioid Consumption
Lasso di tempo: 24 and 48 hours after surgery

Total opioid consumption will be recorded and converted to oral morphine equivalents (OME).

24 and 48 hours after surgery
Postoperative Nausea and Vomiting
Lasso di tempo: 24 and 48 hours after surgery

The incidence of postoperative nausea and vomiting (PONV) will be recorded.

24 and 48 hours after surgery
Time to ambulation
Lasso di tempo: Day 0 (postoperative)

Time from completion of surgery to first postoperative ambulation will be recorded.

Day 0 (postoperative)
Postoperative Thigh Edema
Lasso di tempo: Day 0 and Day 1 after surgery

Postoperative changes in thigh circumference will be measured at three standardized locations: 15 cm above the superior pole of the patella, at the level of the patellar apex, and 10 cm below the patellar apex.

Day 0 and Day 1 after surgery
Postoperative Neuromuscular Recovery of the Thigh
Lasso di tempo: Day 0 and Day 1 after surgery

Neuromuscular recovery will be assessed using the Medical Research Council (MRC) scale, ranging from 0 (no muscle contraction) to 5 (normal muscle strength), across four motor tests: isometric heel press into the mattress, flattening of the popliteal fossa against the mattress, sliding knee flexion/extension, and straight-leg raise at 30 degrees.

Day 0 and Day 1 after surgery
Adverse Events Related to Regional Anesthesia
Lasso di tempo: Day 0

Adverse events related to locoregional anesthesia will be recorded, including signs of local anesthetic systemic toxicity (LAST) and persistent paresthesia.

Day 0
Patient Satisfaction With Analgesic Management
Lasso di tempo: 1 month after surgery

Patient satisfaction with postoperative analgesic management will be assessed using a 5-point Likert scale ranging from 1 (Very dissatisfied) to 5 (Very satisfied). Higher scores indicate greater patient satisfaction and a better outcome.

1 month after surgery

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Yoann ELMALEH, Hôpital Privé Claude Galien

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

15 novembre 2026

Completamento primario (Stimato)

15 novembre 2027

Completamento dello studio (Stimato)

15 novembre 2027

Date di iscrizione allo studio

Primo inviato

30 ottobre 2026

Primo inviato che soddisfa i criteri di controllo qualità

30 ottobre 2026

Primo Inserito (Effettivo)

5 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

6 novembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • COS-RGDS-2025-12-028-P-ELMALEH
  • 2026-A01040-51 (Altro identificatore: ID-RCB)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

INDECISO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .